Inventor · disambiguated record
Lei Chen
Also filed as: CHEN LEI · CHEN LEI L · Chen lei lei
52 granted patents·43 pending applications·239 citations·filing 2001–2025
97Inventor score
Files withZHEJIANG HISUN PHARM CO LTD16SCHERING CORP11XIZANG HAISCO PHARMACEUTICAL CO LTD9JIANGSU HENGRUI MEDICINE CO7HAISCO PHARMACEUTICALS PTE LTD3
Top patents by PatentIndex Score
95 records- 0195US7488745B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2007·Granted Feb 10, 2009·23 cites·34 claims
- 0294US10017543B2Prefusion RSV F proteins and their useUS HEALTH·Filed 2014·Granted Jul 10, 2018·26 cites·58 claims
- 0392US11807635B2Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereofHAISCO PHARMACEUTICALS PTE LTD·Filed 2022·Granted Nov 7, 2023·5 cites·12 claims
- 0492US7524842B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2007·Granted Apr 28, 2009·19 cites·34 claims
- 0592US7504424B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2006·Granted Mar 17, 2009·24 cites·3 claims
- 0691US8569336B2Compounds for the treatment of inflammatory disordersTONG LING·Filed 2009·Granted Oct 29, 2013·44 cites·4 claims
- 0791US7482370B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2005·Granted Jan 27, 2009·20 cites·79 claims
- 0889US2025368690A1Prefusion rsv f proteins and their useTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2024·Application pending·0 cites
- 0988US7879890B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2008·Granted Feb 1, 2011·6 cites·11 claims
- 1087US11981707B2Prefusion RSV F proteins and their useUS HEALTH·Filed 2023·Granted May 14, 2024·0 cites·25 claims
- 1187US11130785B2Prefusion RSV F proteins and their useUS HEALTH·Filed 2018·Granted Sep 28, 2021·2 cites·24 claims
- 1286US7772263B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2009·Granted Aug 10, 2010·7 cites·31 claims
- 1386US7687527B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2008·Granted Mar 30, 2010·8 cites·9 claims
- 1486US7329495B2Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumorsUNIV TEXAS·Filed 2005·Granted Feb 12, 2008·11 cites·12 claims
- 1584US7683085B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2008·Granted Mar 23, 2010·6 cites·10 claims
- 1683US9555038B2Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseasesMERCK SHARP & DOHME·Filed 2013·Granted Jan 31, 2017·6 cites·24 claims
- 1782US7071213B2Cannabinoid receptor ligandsSCHERING CORP·Filed 2002·Granted Jul 4, 2006·16 cites·20 claims
- 1880US12358898B2Pyrimidine derivative, method for preparing same and use thereof in medicineZHEJIANG HISUN PHARM CO LTD·Filed 2023·Granted Jul 15, 2025·0 cites·8 claims
- 1979US9388133B2Pyrrole sulfonamide derivative, preparation method for same, and medical application thereofJIANGSU HANSOH PHARMACEUTICAL CO LTD·Filed 2013·Granted Jul 12, 2016·5 cites·21 claims
- 2075US2022002351A1Prefusion rsv f proteins and their useTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2021·Application pending·0 cites
- 2174US12365673B2Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereofHAISCO PHARMACEUTICALS PTE LTD·Filed 2023·Granted Jul 22, 2025·0 cites·6 claims
- 2274US11384097B2Tetrahydroisoquinoline derivative, preparation method therefor and use thereofZHEJIANG HISUN PHARM CO LTD·Filed 2019·Granted Jul 12, 2022·2 cites·19 claims
- 2373US11535633B2Fused tricyclic heterocycle compounds and therapeutic uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Dec 27, 2022·2 cites·33 claims
- 2471US9375457B2Composition comprising Rhizoma coptidis, Cortex phellodendri and Fructus gardeniae and for treating neurodegenerative diseasesUNIV HONG KONG BAPTIST·Filed 2014·Granted Jun 28, 2016·1 cites·10 claims
- 2570US10987416B2Purification of recombinant EV71 virus-like particle and method for preparing vaccine thereofBEIJING MINHAI BIOTECHNOLOGY CO LTD·Filed 2016·Granted Apr 27, 2021·2 cites·8 claims
- 2669US11827625B2Pyrimidine derivative, method for preparing same and use thereof in medicineZHEJIANG HISUN PHARM CO LTD·Filed 2021·Granted Nov 28, 2023·0 cites·8 claims
- 2769US2023220137A1Method for preparing eva copolymer with high ethylene content by solution polymerization under a low to a medium pressureYUNNAN ZHENGBANG TECH CO LTD·Filed 2022·Application pending·0 cites
- 2867US11001572B2Pyrimidine derivative, method for preparing same and use thereof in medicineZHEJIANG HISUN PHARM CO LTD·Filed 2020·Granted May 11, 2021·0 cites·9 claims
- 2965US10087191B2Piperidine derivative and preparation method and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2016·Granted Oct 2, 2018·1 cites·16 claims
- 3065US7253189B2Cannabinoid receptor ligandsSCHERING CORP·Filed 2003·Granted Aug 7, 2007·2 cites·53 claims
- 3163US10479753B2Sacubitril intermediate and preparation method thereofSUNSHINE LAKE PHARMA CO LTD·Filed 2018·Granted Nov 19, 2019·0 cites·16 claims
- 3262US2025263426A1Pde4b inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3362US2025382250A1Stilbene derivative as ahr agonist and use thereofNANJING GRITPHARMACO LTD·Filed 2023·Application pending·0 cites
- 3461US2025326765A1Pde4b inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3561US2012034254A1Antigenic cloaking and its useKWONG PETER D·Filed 2009·Application pending·0 cites
- 3660US11370739B2Sacubitril intermediate and preparation method thereofNORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD·Filed 2019·Granted Jun 28, 2022·0 cites·16 claims
- 3760US2025154135A1M-choline receptor agonist compound, preparation method therefor and use thereofNANJING GRITPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 3859US10654836B2Pyrimidine derivative, method for preparing same and use thereof in medicineZHEJIANG HISUN PHARM CO LTD·Filed 2017·Granted May 19, 2020·0 cites·16 claims
- 3959US2025340532A1Heterocyclic compound ccr4 inhibitor and user thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 4058US2025000988A1Epha2 bicyclic peptide ligand and conjugate thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 4158US2025346571A1Bicyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 4256US2024391937A1Bicyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 4356US2025034168A1Nitrogen-containing heterocyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 4455US12251435B2Engineered Hansenula fungi efficiently expressing CA10 virus-like particles and uses thereofBEIJING MINHAI BIOTECHNOLOGY CO LTD·Filed 2020·Granted Mar 18, 2025·0 cites·5 claims
- 4555US2024067633A1Ketohexokinase inhibitor and use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 4655US2025222116A1Parp-1 degradation agent and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 4754US2008213774A1Mutations in Kit Confer Imatinib Resistance in Gastrointestinal Stromal TumorsUNIV TEXAS·Filed 2007·Application pending·0 cites
- 4854US2024287044A1Salt of selective fgfr4 inhibitor, and preparation method therefor and application thereofZHEJIANG HISUN PHARM CO LTD·Filed 2022·Application pending·0 cites
- 4954US2024368204A1Small molecular cd73 antagonist and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 5054US2024382475A1Quinazoline Derivative, Or Preparation Method Therefor And Use ThereofZHEJIANG HISUN PHARM CO LTD·Filed 2022·Application pending·0 cites
Showing the top 50 of 95 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Lei Chen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →